Redhill Biophrma ADR (NQ: RDHL )
0.3840 +0.0040 (+1.05%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2023 Add to My Watchlist
All News about Redhill Biophrma ADR
RedHill Biopharma Ltd Announces RedHill: LPI in Part A of RHB-107 P2/3 COVID Study
November 15, 2021
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients Recruitment completed for Part A of the Phase...
RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill
November 08, 2021
RedHill received the first tranche of $5 million in a private placement of restricted stock priced at $6.04 per ADS, representing a 20% premium based on the 30 trading days' volume weighted average...
RedHill Biopharma Presents New Talicia(R) and Movantik(R) Data Analyses at ACG 2021
October 25, 2021
Two new analyses evaluate pharmacological and clinical advantages of Talicia® as first-line H. pylori therapy over clarithromycin-based regimens - Two new analyses of Movantik® data evaluate efficacy...
RedHill Biopharma Announces Insider Buying
October 18, 2021
TEL-AVIV, ISRAEL and RALEIGH, NC / ACCESSWIRE / October 18, 2021 / RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that...
RedHill Biopharma Announces New U.S. Patent Covering Talicia for H. pylori Infection Through 2034 The patent is directed to the Talicia® formulation and pharmaceutical kits for use in the treatment of...
RedHill Biopharma Ltd Announces Talicia(R) added to Medi-Cal CDL
October 06, 2021
RedHill Biopharma's Talicia® added to Medi-Cal Contract Drug List with No Prior Authorization Requirements Addition of Talicia® by Medi-Cal Fee-For-Service (FFS) Contract Drug List (CDL) with no prior...
RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
October 04, 2021
62% statistically significant reduction in mortality shown for moderately severe COVID-19 patients group treated with opaganib vs. the placebo-controlled arm (7 deaths in the 117-patient opaganib arm...